These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 30614563)

  • 1. Latanoprostene bunod ophthalmic solution 0.024%: a new treatment option for open-angle glaucoma and ocular hypertension.
    Fingeret M; Gaddie IB; Bloomenstein M
    Clin Exp Optom; 2019 Nov; 102(6):541-550. PubMed ID: 30614563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.
    Hoy SM
    Drugs; 2018 May; 78(7):773-780. PubMed ID: 29761382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension.
    Kaufman PL
    Expert Opin Pharmacother; 2017 Mar; 18(4):433-444. PubMed ID: 28234563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings.
    Weinreb RN; Liebmann JM; Martin KR; Kaufman PL; Vittitow JL
    J Glaucoma; 2018 Jan; 27(1):7-15. PubMed ID: 29194198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.
    Cavet ME; DeCory HH
    J Ocul Pharmacol Ther; 2018; 34(1-2):52-60. PubMed ID: 28783422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The APOLLO Study.
    Weinreb RN; Scassellati Sforzolini B; Vittitow J; Liebmann J
    Ophthalmology; 2016 May; 123(5):965-73. PubMed ID: 26875002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study.
    Medeiros FA; Martin KR; Peace J; Scassellati Sforzolini B; Vittitow JL; Weinreb RN
    Am J Ophthalmol; 2016 Aug; 168():250-259. PubMed ID: 27210275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma.
    Wang Y; Liao Y; Nie X
    Clinics (Sao Paulo); 2020; 75():e1874. PubMed ID: 33263632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
    Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL;
    Br J Ophthalmol; 2015 Jun; 99(6):738-45. PubMed ID: 25488946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects.
    Araie M; Sforzolini BS; Vittitow J; Weinreb RN
    Adv Ther; 2015 Nov; 32(11):1128-39. PubMed ID: 26563323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.
    Kawase K; Vittitow JL; Weinreb RN; Araie M;
    Adv Ther; 2016 Sep; 33(9):1612-27. PubMed ID: 27457469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2.
    Asrani S; Bacharach J; Holland E; McKee H; Sheng H; Lewis RA; Kopczynski CC; Heah T
    Adv Ther; 2020 Apr; 37(4):1620-1631. PubMed ID: 32166538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.
    Liu JHK; Slight JR; Vittitow JL; Scassellati Sforzolini B; Weinreb RN
    Am J Ophthalmol; 2016 Sep; 169():249-257. PubMed ID: 27457257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Latanoprostene Bunod 0.024% in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: A Meta-Analysis.
    Lo TC; Chen YY; Hung MC; Chou P
    J Clin Med; 2022 Jul; 11(15):. PubMed ID: 35893417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.
    Easthope SE; Perry CM
    Drugs Aging; 2002; 19(3):231-48. PubMed ID: 12027782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
    Mehran NA; Sinha S; Razeghinejad R
    Eye (Lond); 2020 Jan; 34(1):72-88. PubMed ID: 31695162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.
    Harasymowycz P; Royer C; Cui AX; Barbeau M; Jobin-Gervais K; Mathurin K; Lachaine J; Beauchemin C
    Br J Ophthalmol; 2022 May; 106(5):640-647. PubMed ID: 33397657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-Year Experience With Latanoprostene Bunod in Clinical Practice.
    Radell JE; Sharma HK; Auyeung KL; Paul ME; Gagliuso DJ; Chadha N; Tsai JC; Serle JB
    J Glaucoma; 2021 Sep; 30(9):776-780. PubMed ID: 34172630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.
    Impagnatiello F; Bastia E; Almirante N; Brambilla S; Duquesroix B; Kothe AC; Bergamini MVW
    Br J Pharmacol; 2019 Apr; 176(8):1079-1089. PubMed ID: 29669171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.